Pfizer Share Holder Equity 2010-2024 | PFE

Pfizer share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
  • Pfizer share holder equity for the quarter ending March 31, 2024 was $92.558B, a 8.57% decline year-over-year.
  • Pfizer share holder equity for 2023 was $89.288B, a 6.91% decline from 2022.
  • Pfizer share holder equity for 2022 was $95.916B, a 23.82% increase from 2021.
  • Pfizer share holder equity for 2021 was $77.462B, a 22.04% increase from 2020.
Pfizer Annual Share Holder Equity
(Millions of US $)
2023 $89,288
2022 $95,916
2021 $77,462
2020 $63,473
2019 $63,447
2018 $63,758
2017 $71,656
2016 $59,840
2015 $64,998
2014 $71,622
2013 $76,620
2012 $81,678
2011 $82,621
2010 $88,265
2009 $90,446
Pfizer Quarterly Share Holder Equity
(Millions of US $)
2024-03-31 $92,558
2023-12-31 $89,288
2023-09-30 $97,204
2023-06-30 $99,293
2023-03-31 $101,236
2022-12-31 $95,916
2022-09-30 $92,891
2022-06-30 $87,469
2022-03-31 $82,685
2021-12-31 $77,462
2021-09-30 $75,967
2021-06-30 $70,315
2021-03-31 $68,865
2020-12-31 $63,473
2020-09-30 $65,495
2020-06-30 $64,564
2020-03-31 $65,338
2019-12-31 $63,447
2019-09-30 $65,396
2019-06-30 $59,924
2019-03-31 $59,158
2018-12-31 $63,758
2018-09-30 $71,664
2018-06-30 $70,124
2018-03-31 $70,541
2017-12-31 $71,656
2017-09-30 $61,110
2017-06-30 $58,694
2017-03-31 $58,746
2016-12-31 $59,840
2016-09-30 $63,601
2016-06-30 $63,066
2016-03-31 $63,347
2015-12-31 $64,998
2015-09-30 $67,124
2015-06-30 $67,180
2015-03-31 $67,587
2014-12-31 $71,622
2014-09-30 $78,305
2014-06-30 $76,956
2014-03-31 $78,068
2013-12-31 $76,620
2013-09-30 $78,354
2013-06-30 $78,977
2013-03-31 $82,827
2012-12-31 $81,678
2012-09-30 $82,115
2012-06-30 $79,961
2012-03-31 $83,677
2011-12-31 $82,621
2011-09-30 $90,530
2011-06-30 $88,963
2011-03-31 $90,533
2010-12-31 $88,265
2010-09-30 $88,068
2010-06-30 $86,878
2010-03-31 $90,082
2009-12-31 $90,446
2009-09-30 $66,250
2009-06-30 $63,235
2009-03-31 $60,441
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $156.738B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $824.287B 119.14
Novo Nordisk (NVO) Denmark $642.884B 49.40
Johnson & Johnson (JNJ) United States $349.955B 13.90
Merck (MRK) United States $329.771B 60.00
AbbVie (ABBV) United States $293.293B 15.15
AstraZeneca (AZN) United Kingdom $248.255B 21.58
Novartis AG (NVS) Switzerland $215.744B 15.30
Sanofi (SNY) $122.543B 11.56
Innoviva (INVA) United States $0.993B 6.97